SOUTH SAN FRANCISCO, Calif., July 29 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, today announced that Ronald A. Martell, president and chief operating officer, will participate in two upcoming conferences in August during which he will provide a corporate overview, including a discussion of the clinical development program and regulatory strategy for picoplatin, the Company’s lead product candidate.
* Oppenheimer & Co. Inc.'s Small & Mid Cap Clinical & Regulatory Conference on Monday, August 4, at 8:40 a.m. Eastern Time at the Oppenheimer office in New York. Mr. Martell will discuss Poniard’s clinical development programs and regulatory strategy, and then participate in a subsequent panel discussion, entitled “Designing A Pivotal Program with an Eye Towards Approval.” During this discussion, which begins at 9:55 a.m., Mr. Martell will discuss the regulatory path to approval for picoplatin.
* BMO Capital Markets’ 2008 Focus on Healthcare Conference on Tuesday, August 5, at 9:00 a.m. Eastern Time at the Millennium Broadway Hotel in New York.
A live audio webcast of each Poniard presentation will be available for 10 business days on the “Events” page of the “News & Events” section of the Company’s website at http://www.poniard.com.
About Poniard Pharmaceuticals
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company’s lead platform product candidate, is a new generation platinum therapy with an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and hormone-refractory prostate cancers, as well as a clinical trial of oral picoplatin in solid tumors. Picoplatin has not been approved by any regulatory authority for use in humans. For additional information please visit http://www.poniard.com.
(C) 2008 Poniard Pharmaceuticals, Inc. All Rights Reserved. Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.
CONTACT: Brendan Doherty, Corporate Communications of Poniard
Pharmaceuticals, Inc., +1-650-745-4425, bdoherty@poniard.com
Web site: http://www.poniard.com/
